drugset / Trial / NCT04851964

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964

Phase 3 Completed 416 enrolled AstraZeneca Amgen · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

Timeline

Start
2021-04-22
Primary completion
2024-09-23
Completion
2024-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tezepelumab Monoclonal antibody 210 mg Subcutaneous
Background Mometasone furoate Other / unclassified Intranasal